Feasibility, Acceptability and Directional Signal Effect on Blood Folate Levels of Iodized Salt Fortified With Folic Acid: Clinical Study

NCT ID: NCT05935631

Last Updated: 2023-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-24

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim 1: Assess directional signal of effect of fortified salt with folic acid and iodine on blood serum folate levels.

It will be accomplished by feasibility pre-test/post-test clinical study by estimating mean and variability of serum blood folate levels effects of folic acid fortified salt.

Hypothesis: Fortified salt with folic acid and iodine will increase serum blood folate levels from baseline by month 1.

Aim 2: Assess feasibility and acceptability of salt fortified with folic acid and iodine.

Feasibility will be measured by 1) subjects' refusal rate of consent by 30 subjects during 6-month enrollment period; 2) method of determining salt consumption (weighting the saltshaker pre and post); 3) completion rates of study protocols from baseline to follow up. Hypothesis 1a: Completion of all blood draw visits will be 90-100%.

Acceptability will be measured by 1) completion rate of daily salt logs; 2) consumption of salt by weighting saltshakers; 3) attitude towards taste and color difference. Hypothesis 1b: Completion rate (90-100%) of daily salt logs will range from 90-100% of participants and 2) consumption of salt will range from 90-100% of participants.

Dietary surveys will be employed to document dietary habits and estimated daily FA intake in the sample population. Feasibility and acceptability of dietary surveys will be measured by willingness to answer survey questions. Hypothesis 1c: Completion rate of dietary surveys will range 90-100%.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neural Tube Defects Folic Acid Deficiency Fortification

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Pre-test and post-test of serum folate levels after using salt with folic acid in the same group of women, each serving as their own control.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Salt with folic acid and iodine

Intervention is intake of double fortified salt with folic acid and iodine (DFS). We will ask the participants to substitute their current salt with the study saltshaker and use it when preparing food or when eating out. We estimate minimum daily intake from salt consumption by participants will be 200 micrograms (µg) of folic acid per serving. Serving is 2g of salt. Participants will be given portion suggestions: 1/2 teaspoon or 2-3 pinches or 8-10 shakes/5 times a day. Containers (125g) will be weighted at the beginning and end of 1 month. We will ask each day if woman cooked/used the salt for herself only or to list number of people each day. Participants will also agree to complete either daily paper salt log. A commercially available salt that is fortified with folic acid has been provided by AlpenJodSalz produced by Sudwestdeutsche Salzwerk. For 30 participants, we will need 30 containers.

Group Type EXPERIMENTAL

Salt with folic acid and iodine

Intervention Type DIETARY_SUPPLEMENT

Assess serum and RBC folate levels in women at baseline and 1 month after ingesting salt with folic acid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Salt with folic acid and iodine

Assess serum and RBC folate levels in women at baseline and 1 month after ingesting salt with folic acid

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women
* consumes salt

Exclusion Criteria

* pregnant or intends to become pregnant in next 6 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Alabama at Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anastasia Arynchyna

Clinical Research Manager/ DrPH student

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anastasia Arynchyna-Smith, MPH

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Kancherla V, Wagh K, Pachon H, Oakley GP Jr. A 2019 global update on folic acid-preventable spina bifida and anencephaly. Birth Defects Res. 2021 Jan 1;113(1):77-89. doi: 10.1002/bdr2.1835. Epub 2020 Oct 30.

Reference Type BACKGROUND
PMID: 33124747 (View on PubMed)

Kancherla V, Tsang B, Wagh K, Dixon M, Oakley GP Jr. Modeling shows high potential of folic acid-fortified salt to accelerate global prevention of major neural tube defects. Birth Defects Res. 2020 Nov;112(18):1461-1474. doi: 10.1002/bdr2.1769. Epub 2020 Aug 1.

Reference Type BACKGROUND
PMID: 32738033 (View on PubMed)

Blencowe H, Kancherla V, Moorthie S, Darlison MW, Modell B. Estimates of global and regional prevalence of neural tube defects for 2015: a systematic analysis. Ann N Y Acad Sci. 2018 Feb;1414(1):31-46. doi: 10.1111/nyas.13548. Epub 2018 Jan 24.

Reference Type BACKGROUND
PMID: 29363759 (View on PubMed)

Allen R, James A, Sankaran S. Trends in termination of pregnancy for neural tube defects in England and Wales from 2007 to 2017: Observational prospective study. Prenat Diagn. 2021 Dec;41(13):1624-1633. doi: 10.1002/pd.6060. Epub 2021 Oct 26.

Reference Type BACKGROUND
PMID: 34671992 (View on PubMed)

Lynberg MC, Khoury MJ. Contribution of birth defects to infant mortality among racial/ethnic minority groups, United States, 1983. MMWR CDC Surveill Summ. 1990 Jul;39(3):1-12.

Reference Type BACKGROUND
PMID: 2115106 (View on PubMed)

Hopson B; MSHA; Alford EN, Zimmerman K, Blount JP, Rocque BG. Development of an evidence-based individualized transition plan for spina bifida. Neurosurg Focus. 2019 Oct 1;47(4):E17. doi: 10.3171/2019.7.FOCUS19425.

Reference Type BACKGROUND
PMID: 31574471 (View on PubMed)

Crider KS, Devine O, Hao L, Dowling NF, Li S, Molloy AM, Li Z, Zhu J, Berry RJ. Population red blood cell folate concentrations for prevention of neural tube defects: Bayesian model. BMJ. 2014 Jul 29;349:g4554. doi: 10.1136/bmj.g4554.

Reference Type BACKGROUND
PMID: 25073783 (View on PubMed)

Estevez-Ordonez D, Davis MC, Hopson B; MSHA; Arynchyna A, Rocque BG, Fieggen G, Rosseau G, Oakley G; MSPM; Blount JP. Reducing inequities in preventable neural tube defects: the critical and underutilized role of neurosurgical advocacy for folate fortification. Neurosurg Focus. 2018 Oct;45(4):E20. doi: 10.3171/2018.7.FOCUS18231.

Reference Type BACKGROUND
PMID: 30269587 (View on PubMed)

Oumer M, Tazebew A, Silamsaw M. Birth prevalence of neural tube defects and associated risk factors in Africa: a systematic review and meta-analysis. BMC Pediatr. 2021 Apr 21;21(1):190. doi: 10.1186/s12887-021-02653-9.

Reference Type BACKGROUND
PMID: 33882899 (View on PubMed)

Williams J, Mai CT, Mulinare J, Isenburg J, Flood TJ, Ethen M, Frohnert B, Kirby RS; Centers for Disease Control and Prevention. Updated estimates of neural tube defects prevented by mandatory folic Acid fortification - United States, 1995-2011. MMWR Morb Mortal Wkly Rep. 2015 Jan 16;64(1):1-5.

Reference Type BACKGROUND
PMID: 25590678 (View on PubMed)

Kancherla V, Wagh K, Priyadarshini P, Pachon H, Oakley GP Jr. A global update on the status of prevention of folic acid-preventable spina bifida and anencephaly in year 2020: 30-Year anniversary of gaining knowledge about folic acid's prevention potential for neural tube defects. Birth Defects Res. 2022 Dec 1;114(20):1392-1403. doi: 10.1002/bdr2.2115. Epub 2022 Nov 7.

Reference Type BACKGROUND
PMID: 36345648 (View on PubMed)

Wang A, Rose CE, Qi YP, Williams JL, Pfeiffer CM, Crider KS. Impact of Voluntary Folic Acid Fortification of Corn Masa Flour on RBC Folate Concentrations in the U.S. (NHANES 2011-2018). Nutrients. 2021 Apr 16;13(4):1325. doi: 10.3390/nu13041325.

Reference Type BACKGROUND
PMID: 33923768 (View on PubMed)

Fan L, Meng F, Sun Q, Zhai Y, Liu P. Assessment of Sustainable Elimination Criteria for Iodine Deficiency Disorders Recommended by International Organizations. Front Nutr. 2022 Apr 13;9:852398. doi: 10.3389/fnut.2022.852398. eCollection 2022.

Reference Type BACKGROUND
PMID: 35495946 (View on PubMed)

Liu T, Li Y, Teng D, Shi X, Yan L, Yang J, Yao Y, Ye Z, Ba J, Chen B, Du J, He L, Lai X, Teng X, Li Y, Chi H, Liao E, Liu C, Liu L, Qin G, Qin Y, Quan H, Shi B, Sun H, Tang X, Tong N, Wang G, Zhang JA, Wang Y, Xue Y, Yang L, Zhang Q, Zhang L, Zhu J, Zhu M, Shan Z, Teng W. The Characteristics of Iodine Nutrition Status in China After 20 Years of Universal Salt Iodization: An Epidemiology Study Covering 31 Provinces. Thyroid. 2021 Dec;31(12):1858-1867. doi: 10.1089/thy.2021.0301. Epub 2021 Dec 2.

Reference Type BACKGROUND
PMID: 34806437 (View on PubMed)

Mokhort T, Petrenko S, Leushev B, Fedorenko E, Kolomiets N, Mokhort A. Assessment of iodine status among school age children and pregnant women of Belarus in 2017-2018. Clinical and experimental thyroidology. 11/13 2018;14doi:10.14341/ket9732

Reference Type BACKGROUND

Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet. 1991 Jul 20;338(8760):131-7.

Reference Type BACKGROUND
PMID: 1677062 (View on PubMed)

Chen MY, Rose CE, Qi YP, Williams JL, Yeung LF, Berry RJ, Hao L, Cannon MJ, Crider KS. Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation. Am J Clin Nutr. 2019 May 1;109(5):1452-1461. doi: 10.1093/ajcn/nqz027.

Reference Type BACKGROUND
PMID: 31005964 (View on PubMed)

Eldridge C, Bandlamuri S, Andrews JG, Galindo MK, Contreras D, Flood TJ, Rice S. Postfolate spina bifida lesion level change. Birth Defects Res. 2018 Jul 3;110(11):949-955. doi: 10.1002/bdr2.1221. Epub 2018 Mar 25.

Reference Type BACKGROUND
PMID: 29575817 (View on PubMed)

McDowell MA, Lacher DA, Pfeiffer CM, Mulinare J, Picciano MF, Rader JI, Yetley EA, Kennedy-Stephenson J, Johnson CL. Blood folate levels: the latest NHANES results. NCHS Data Brief. 2008 May;(6):1-8.

Reference Type BACKGROUND
PMID: 19389320 (View on PubMed)

Pfeiffer CM, Sternberg MR, Zhang M, Fazili Z, Storandt RJ, Crider KS, Yamini S, Gahche JJ, Juan W, Wang CY, Potischman N, Williams J, LaVoie DJ. Folate status in the US population 20 y after the introduction of folic acid fortification. Am J Clin Nutr. 2019 Nov 1;110(5):1088-1097. doi: 10.1093/ajcn/nqz184.

Reference Type BACKGROUND
PMID: 31504109 (View on PubMed)

Hopson B, Shamblin I, Zimmerman K, Rocque B, Salehani A, Blount JP. Scope of care in the first four years of life for individuals born with myelomeningocele: A single institution experience1. J Pediatr Rehabil Med. 2021;14(4):667-673. doi: 10.3233/PRM-200803.

Reference Type BACKGROUND
PMID: 34864701 (View on PubMed)

Rocque BG, Bishop ER, Scogin MA, Hopson BD, Arynchyna AA, Boddiford CJ, Shannon CN, Blount JP. Assessing health-related quality of life in children with spina bifida. J Neurosurg Pediatr. 2015 Feb;15(2):144-9. doi: 10.3171/2014.10.PEDS1441. Epub 2014 Nov 21.

Reference Type BACKGROUND
PMID: 25415252 (View on PubMed)

Mai CT, Evans J, Alverson CJ, Yue X, Flood T, Arnold K, Nestoridi E, Denson L, Adisa O, Moore CA, Nance A, Zielke K, Rice S, Shan X, Dean JH, Ethen M, Hansen B, Isenburg J, Kirby RS. Changes in Spina Bifida Lesion Level after Folic Acid Fortification in the US. J Pediatr. 2022 Oct;249:59-66.e1. doi: 10.1016/j.jpeds.2022.06.023. Epub 2022 Jun 27.

Reference Type BACKGROUND
PMID: 35772508 (View on PubMed)

Mai CT, Isenburg J, Langlois PH, Alverson CJ, Gilboa SM, Rickard R, Canfield MA, Anjohrin SB, Lupo PJ, Jackson DR, Stallings EB, Scheuerle AE, Kirby RS; National Birth Defects Prevention Network. Population-based birth defects data in the United States, 2008 to 2012: Presentation of state-specific data and descriptive brief on variability of prevalence. Birth Defects Res A Clin Mol Teratol. 2015 Nov;103(11):972-93. doi: 10.1002/bdra.23461. No abstract available.

Reference Type BACKGROUND
PMID: 26611917 (View on PubMed)

Grosse SD, Berry RJ, Mick Tilford J, Kucik JE, Waitzman NJ. Retrospective Assessment of Cost Savings From Prevention: Folic Acid Fortification and Spina Bifida in the U.S. Am J Prev Med. 2016 May;50(5 Suppl 1):S74-S80. doi: 10.1016/j.amepre.2015.10.012. Epub 2016 Jan 11.

Reference Type BACKGROUND
PMID: 26790341 (View on PubMed)

McGee EJT, Sangakkara AR, Diosady LL. Double fortification of salt with folic acid and iodine. Journal of Food Engineering. 2017/04/01/ 2017;198:72-80. doi:https://doi.org/10.1016/j.jfoodeng.2016.11.019

Reference Type BACKGROUND

Modupe O, Krishnaswamy K, Diosady LL. Technology for Triple Fortification of Salt with Folic Acid, Iron, and Iodine. J Food Sci. 2019 Sep;84(9):2499-2506. doi: 10.1111/1750-3841.14730. Epub 2019 Aug 8.

Reference Type BACKGROUND
PMID: 31393020 (View on PubMed)

Modupe O, Siddiqui J, Jonnalagadda A, Diosady LL. Folic acid fortification of double fortified salt. Sci Rep. 2021 Jul 15;11(1):14561. doi: 10.1038/s41598-021-93194-9.

Reference Type BACKGROUND
PMID: 34267239 (View on PubMed)

Li YO, Diosady LL, Wesley AS. Folic acid fortification through existing fortified foods: iodized salt and vitamin A-fortified sugar. Food Nutr Bull. 2011 Mar;32(1):35-41. doi: 10.1177/156482651103200104.

Reference Type BACKGROUND
PMID: 21560462 (View on PubMed)

Puri S, Rekhi TK, Thomas T, Jadhav MH, Mannar V, Diosady LL. Sensory Trial of Quintuple Fortified Salt-Salt Fortified With Iodine, Iron, Folic Acid, Vitamin B12, and Zinc-Among Consumers in New Delhi, India. Food Nutr Bull. 2022 Sep;43(3):340-350. doi: 10.1177/03795721221078361. Epub 2022 May 8.

Reference Type BACKGROUND
PMID: 35531896 (View on PubMed)

Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016 Oct 24;355:i5239. doi: 10.1136/bmj.i5239.

Reference Type BACKGROUND
PMID: 27777223 (View on PubMed)

Exchange GFD. Dashboard: Country Fortification. 2022. https://fortificationdata.org/country-fortification-dashboard/?alpha3_code=USA&lang=en

Reference Type BACKGROUND

Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, Engell RE, Lim SS, Danaei G, Mozaffarian D; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE). Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open. 2013 Dec 23;3(12):e003733. doi: 10.1136/bmjopen-2013-003733.

Reference Type BACKGROUND
PMID: 24366578 (View on PubMed)

Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985 Jul;122(1):51-65. doi: 10.1093/oxfordjournals.aje.a114086.

Reference Type BACKGROUND
PMID: 4014201 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

300009522

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.